### AstraZeneca – Call For Grant Applications  
**(CGA Respiratory ATS 2022 Severe Asthma Epithelial Cytokines Emerging Therapies 2021-07)**

<table>
<thead>
<tr>
<th>Submission Deadline</th>
<th>Accepting applications until 9 am EST on August 30, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Area of Focus</td>
<td>Respiratory</td>
</tr>
<tr>
<td>Therapeutic Area</td>
<td>Severe asthma</td>
</tr>
</tbody>
</table>

#### Need

Airway diseases are heterogeneous in nature, with inflammation resulting from complex interactions between airway structural cells and the innate/adaptive immune system.

Specific epithelial cytokines (also referred to as alarmins, e.g. IL-25, IL-33, and TSLP) have been identified as upstream mediators/triggers of the inflammatory response in asthma as well as other airway diseases, and there is clinical trial data supporting their potential role in the treatment of severe asthma.

Pulmonary care professionals and researchers who manage patients with severe asthma should be able to describe the role that epithelial alarmins play in airway disease pathophysiology and the results of clinical trials investigating biologics that target these cytokines, as well as, envision how the trial results can be translated into clinical practice to improve patient outcomes.

#### Educational Program

Consisting of, but not limited to, a live, virtual non-CME program held during the ATS International Conference in an industry program time slot. Following ATS, an on-demand accredited activity to reach a broader audience.

#### Budget

| Budget | ≤ $330,000.00 |

#### Successful submission

- Independently-developed application, providing rationale for and detailed description of the goals, learning objectives, educational strategy, format, execution and measurement of program
- Proposed activities will:
  - build upon content included in previously-executed programs and in presently available activities
  - leverage the latest digital technologies for learner engagement, including multimedia elements and learner interactivity with faculty and content
  - employ educational strategies for maximal retention and application of content by tailoring to the specific needs of and learning styles of the proposed audience
  - include a synchronous live stream
- Meaningful outcomes from previously executed program with similar goal and format
- Ability to achieve Level 4 outcomes, report monthly metrics / quarterly outcomes (broken down by specialty, profession and geography)

#### CGA Code

CGA Respiratory ATS 2022 Severe Asthma Epithelial Cytokines Emerging Therapies 2021-07

#### Website URL

https://www.astrazenecagrants.com/us-grants.html
**Program Requirements:**

The Program must be planned and executed as an accredited activity and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration’s Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and, if applicable, accreditation standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.